Ardea Biosciences, Inc. (Nasdaq: RDEA) announces positive top-line results from a Phase 2b combo study of RDEA594 in Allopurinaol-Refractory gout ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE